Guest Posted June 22, 2010 Share Posted June 22, 2010 Analysts predict between £50m and £60m of peak annual sales for Sativex by 2015, with GW receiving between 20 and 30 per cent of that. The approval of Sativex provides a boost to GW’s development programme to create other cannabis-based medicines. Trials are already underway on cannabis-based medicines to treat epilepsy and psychosis, and GW is seeking approval from US regulators for the marketing of Sativex as a treatment for cancer pain http://www.ft.com/cms/s/0/1e5e5e06-7d2f-11df-8845-00144feabdc0.html Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.